Di Costanzo, F.; Di Costanzo, F.; Antonuzzo, L.; Mazza, E.; Giommoni, E.
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers 2023, 15, 416.
https://doi.org/10.3390/cancers15020416
AMA Style
Di Costanzo F, Di Costanzo F, Antonuzzo L, Mazza E, Giommoni E.
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers. 2023; 15(2):416.
https://doi.org/10.3390/cancers15020416
Chicago/Turabian Style
Di Costanzo, Francesco, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, and Elisa Giommoni.
2023. "Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine" Cancers 15, no. 2: 416.
https://doi.org/10.3390/cancers15020416
APA Style
Di Costanzo, F., Di Costanzo, F., Antonuzzo, L., Mazza, E., & Giommoni, E.
(2023). Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers, 15(2), 416.
https://doi.org/10.3390/cancers15020416